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Background: Breast cancer patients experience weight changes during treatment, which adversely affect prognosis. 
However, cancer treatment in Kenya mainly focuses on tumor eradication with limited attention on weight 
management interventions.  
Objectives: To determine weight changes and associated factors among breast cancer patients receiving the first 
three cycles of chemotherapy at Kenyatta National Hospital.  
Methodology: A prospective cohort design was adopted. One hundred and forty two female participants aged 18-70 
years diagnosed with stage 1, 2 and 3 breast cancers were followed up for three months during treatment. Data was 
collected after every visit using a structured questionnaire, individual dietary diversity tool and anthropometric 
assessments. Clinical data was extracted from participant’s medical records. Frequencies, proportions, measures of 
central tendency and chi square tests were utilized in analysis.  
Results:  The majority of patients (59.2%) had stage 2 breast cancers. The prevalent type of cancer was ductal 
carcinoma (97.9%). Most of the patients were on adjuvant chemotherapy (66.9%). The mean weight (SD) was 
66.6(13.6) kg, 65.9(13.4) kg and 66.1(13.2) kg at first, second and third cycles respectively. Overall (between the first 
and thirst cycle), the mean weight change (SD) was 0.4(1.6) kg. Majority (48.4%) gained weight and among them, 
24.2% gained 2kg and 18.3% gained 1kg. Amidst the patients who lost weight, 19.2% and 11.7% lost 1kg and 2 kgs 
respectively. Weight gain was significantly (p<0.05) associated with being married and Body Mass Index (BMI) at 
baseline. On the other hand, weight loss was significantly (p<0.05) associated with diarrhea. 
Conclusion: Weight changes were observed among the patients with majority of them experiencing weight gain than 
weight loss hence a need for early initiation of weight management interventions after diagnosis of breast cancer. 
Key words: Breast cancer, weight gain, chemotherapy 
Received: April, 2017  
Published: August, 2017 
 
1. Introduction 
According to the International Agency for Research on 
Cancer (IARC), breast cancer is the 2nd leading cause of 
cancer specific mortality in developing countries(Ferlay 
et al, 2015). In Kenya, one in every two women 
diagnosed of cancer either present with cervical or 
breast cancer (Korir et al, 2014). A study carried out in 
Kenyatta National Hospital showed breast cancer (55%) 
as the most prevalent cancer among females(Muthike 
Caroline, 2013). Excess Body weight has been proven a 
risk factor and main prognostic factor for breast cancer. 
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Cytotoxic treatments like chemotherapy cause weight 
gain and alter the metabolic status of breast cancer 
patients (Bicakli et al, 2016). Agreeably, weight gain is a 
common problem among breast cancer patients who 
receive adjuvant chemotherapy and this increases the 
risk of metabolic syndrome among premenopausal 
patients (Bicakli et al, 2016; Demark-Wahnefried, 
Campbell & Hayes, 2012). Similarly, observational 
studies indicate that breast cancer mortality is 33% 
higher in obese than non- obese survivors (Calle, et al, 
2003) 
Weight gain rather than weight loss often occurs after 
breast cancer diagnosis(Yaw et al, 2011). Elevated 
weight gain has been associated with higher risk of 
metabolic diseases which in turn result in poor quality 
of life, leading to decreased overall survival (Calle et al, 
2003). Factors that predispose breast cancer patients to 
weight gain include; early menopause as a result of 
chemotherapy that leads to changes in body 
composition, use of corticosteroids in management of 
nausea during chemotherapy, increased levels of fatigue 
and lethargy and the intense craving of energy rich 
foods during chemotherapy sessions (Melinda, 2015). 
This eventually leads to overweight and obesity which 
puts the patient at risk of diabetes, high blood pressure 
and heart diseases that decrease the quality of life or 
eventually lead to death(PDQ Supportive and Palliative 
Care Editorial Board, 2002). In overweight and obese 
patients, the risk of breast cancer recurrence  is high 
because of the excess adipose tissue which indirectly 
activates tumor proliferation and release of circulating 
estrogen that accelerate proliferation of cancer 
cells(Calle et al, 2003; PDQ Supportive and Palliative 
Care Editorial Board, 2002).  
On the other hand, weight loss during cancer treatment 
affects the severity and progress of disease leading to 
complications and mortality. Upto 45% of cancer 
patients experience weight loss greater than 10% usual 
body weight (Tilton, 2011). The Kenya National 
Guidelines on the management of Cancer 2012 indicate 
that underweight is a common problem in cancer 
prognosis that results to adverse outcomes with 
increased morbidity and mortality as well as decreased 
quality of life (Ministry of Health, 2013). Weight loss, 
the most common secondary diagnosis in cancer 
patients occurs as a result of chemotherapy and tumor 
induced side effects such as anorexia, early satiety, 
altered taste and smell, physical inability to ingest and 
digest food, mal absorption of macro and micro 
nutrients and cancer reduced abnormalities such as 
glucose intolerance, insulin resistance and increased 
lipolysis (PDQ Supportive and Palliative Care Editorial 
Board, 2002). These results to wasting, body weakness, 
immune suppression, reduced protein synthesis, poor 
quality of life and eventually death. Furthermore cancer 
induced abnormalities in metabolism also lead to 
cachexia (where the rate of catabolism is higher than 
anabolism due to the changes in metabolism induced by 
the tumor and chemotherapy). However breast cancer 
patients present more with weight gain than weight loss 
(Ministry of Health, 2013). 
 Weight management among breast cancer patients on 
chemotherapy is key to achieving better response to 
treatment, good quality of life and better survival rates. 
The risk of weight gain or weight loss is high among 
breast cancer patients and this has a negative effect on 
the treatment outcomes. Kenya National Cancer 
management guidelines point towards maintaining 
ideal weight during cancer treatment. However this has 
not been implemented among most cancer patients in 
Kenya. Poor prognosis and a rise in mortality and breast 
cancer recurrence among female patients in Kenya is 
gradually becoming a common occurrence.  In 2012, 
44% of 4,465 registered breast cancer cases in Nairobi 
died (Korir et al, 2014). In addition, despite the known 
effects of weight on treatment outcomes of breast 
cancer patients, cancer experts focus mainly on 
removing the tumor with limited attention on other 
health related interventions such as weight 
management that could potentially be contributing to 
breast cancer recurrence and deaths. The overall goal of 
this study was to determine the weight changes and 
associated factors among early stage breast cancer 
patients receiving the first three cycles of chemotherapy 
at Kenyatta National Hospital. 
2. Methods 
2.1 Study Site 
The study adopted a prospective cohort study design 
where participants were followed up for 3 months 
during which they completed the first three cycles of 
chemotherapy. The study was carried out at the 
oncology outpatient clinic in Kenyatta National Hospital 
where all the cancer outpatients receive their 
chemotherapy.  
2.2 Study population and Eligibility Criteria 
The study targeted all female breast cancer outpatients 
receiving chemotherapy at Kenyatta National Hospital.  
Female patients aged 18 - 70 years, diagnosed with 
stage 1, 2 and 3 breast cancer who had enrolled for or 
had received their first cycle of chemotherapy and gave 
consent were included in the study. The study excluded 
patients who did not consent 
2.3 Sample size and sampling methods 
Systematic random sampling was used to select 142 
participants identified from medical records and every 
third patient selected from the list. Participants were 
interviewed and assessed on the dates they came for 
chemotherapy sessions. 
2.4 Data collection and Research variables 
A structured questionnaire was used to collect data on 
socio-demographic information and factors affecting 
changes in weight. Data on dietary practices was 
collected using an individual dietary diversity tool 
adopted from Food and Agriculture Organization (FAO, 
2013). A cancer abstract form adopted from Nairobi 
Cancer Registry (Korir et al, 2014) was incorporated in 
the tool and used to extract clinical data (type of breast 
cancer, stage of cancer type of chemotherapy and drugs 
administered) from patients’ medical records. 
Participants’ weight and height were assessed after 
every cycle. Using the FAO 2013 standardized 
individual dietary diversity score tool, the respondents 
were asked whether they had consumed foods from 14 
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food groups in the last 24 hrs after every cycle to 
determine level of diet quality consumed. The food 
groups were categorized based on the FAO guidelines as 
follows; 
Cereals Organ meats 
Fruits rich in Vitamin A Legumes and nuts 
Eggs Sugar and honey 
Fish Other roots and tubers  
Fats and oils Other meats 
Roots/tubers & vegetables 
with orange flesh 
Other fruits and 
vegetables 
Dark green leafy 
vegetables 
Milk and dairy Products 
 
This standardized tool uses a recommended reference 
period of the previous 24 hrs because it is less subject 
to the recall error, less cumbersome for the respondent 
and also conforms to the recall time period used in 
many dietary diversity studies (Arimond, 2004; 
Kennedy, 2007; Steyn, 2006). Additionally analysis of 
24 hr based data is easier compared to longer reference 
periods that result into less accurate information due to 
imperfect recall. Data was double entered into MS-
Access database, data cleaning and validation was 
performed and later the data exported to SPSS version 
20.0 for analysis 
2.5 Data Analysis 
Weight of study participants was assessed using digital 
weighing scales after every chemotherapy cycle. Body 
Mass Index (BMI) was calculated from the weight and 
height data collected after every cycle of chemotherapy. 
The participant’s nutrition status as defined by BMI was 
then determined by classifying calculated BMI as 
underweight, normal and overweight & obesity using 
the WHO cut off points as shown below: 
Underweight -  Below 18.5 kg/m2 
Normal  -  18.5-24.9 kg/m2 
Overweight and Obesity -  >25.0kg/m2 
 
Changes in weight were determined by computing 
differences in weight between the first and second cycle 
(midline weight change) and differences in weight 
between the first and third cycle (overall weight 
change). These weight changes were further 
categorized into: Weight gain (positive change), Weight 
loss (negative change) and No change (weight change is 
zero).  
Diet diversity scores were used to determine diet 
adequacy and diet variety consumed by the 
participants.  The levels of adequacy of dietary diversity 
were derived using mean individual dietary diversity 
scores based on the FAO guidelines(FAO, 2013). A score 
of 1 was given to each food group consumed and total 
scores recorded. The diversity scores were further 
classified into; adequate dietary diversity and 
inadequate dietary diversity. A score of 14 was 
considered adequate dietary diversity while a score less 
than 14 was considered inadequate dietary diversity 
score.  
Descriptive statistics were  used to summarize 
categorical variables and measures of central tendency 
used for continuous variables. Student T test was used 
to compare mean differences between weight changes 
among participants. Pearson’s Chi-square test was used 
to test strength of association between categorical 
variables. The threshold for statistical significance was 
set at α = 0.05 and a two-sided p value at 95% 
confidence intervals (CI) reported for corresponding 
analysis.  
2.6 Ethical Considerations 
The protocol was submitted to Institutional Research 
and Ethics Committee (IREC) of Moi University 
Approval number FAN: IREC 1473 and the Kenyatta 
National Hospital /University of Nairobi Ethics and 
Review Committee for ethical approval, number 
P164/03/2015. Participation was fully voluntary and 
confidentiality was observed at all times. Only patients 
who provided written consent were included in the 
study. Data was kept confidential and was only available 
to the research team. No identifiable details of the 
participants were disclosed during the study period. 
There were no foreseeable physical risks associated and 
no direct material benefits to the study participants.  
3. Results  
The mean (SD) age of patients was 48.6 (11.9) years. 
More than half of participants (58.5%) were at 
premenopausal age and unemployed (58.5%) as shown 
in Table 1.  
Diagnosis and the type of drugs used 
Over half of the participants (59.2%) had stage 2 breast 
cancer. The majority was diagnosed with ductal 
carcinoma (97.9%) and was receiving adjuvant 
chemotherapy (66.9%). With respect to chemotherapy 
drugs, participants were on a combination of drugs 
including anthracyclines (adriamycin and epirubicin), 
taxanes, (paclitaxel, taxol, docetaxel,), corticosteroids 
(dexamethasone, prednisolone and methyl 
prednisolone), alkylating agents (cyclophosphamide), 
antimetabolites (5-fluorouracil), and platinum drugs 
(carboplatin). Amid drug combinations, the top most 
received drugs were alkylating agents (39.7%) followed 
by anthracyclines (27%) and corticosteroids (10.5%) as 
shown in Table 2. 
Weight and Body Mass Index of Participants  
The mean weight (SD) of participants was 66.6 (13.6) 
kg, 65.9 (13.4) kg and 66.1 (13.2) kg during first, second 
and third cycle.  
The mean (SD) BMI was 25.8 (4.9), 25.7 (4.9) and 25.5 
(5.0) at first, second and third cycles of chemotherapy. 
During first cycle, the highest proportion (53.5%) of 
participants were overweight and obese. This data is 
shown in Table 3. 
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    Table 1: Socio Demographic Characteristics of study participants 
Variable                                                      n                          % 
Age (n= 142) 
 
 







Occupation  Employed 59 41.5 
 Unemployed 83 58.5 
Marital Status  Married 101 71.1 
 Single 21 14.8 
 Divorced 6 4.2 
 Separated 4 2.8 
Religion  Christian 141 99.3 
 Muslim 1 0.7 
Level of Education  No formal education 20 14.1 
 Primary school 53 37.3 
 Secondary school 53 37.3 
 College 16 11.3 
 
   Table 2: Patient Clinical Information 
Variable Description 






Type of cancer Ductal Carcinoma 139 (97.9) 126 (97.7) 118 (97.5) 
Lobular Carcinoma 2 (1.4) 2 (1.6) 2 (1.7) 
Stage of the cancer Stage 1 17 (11.9) 19 (14.7) 18 (16.5) 
Stage 2 84 (59.2) 72 (55.8) 64 (52.9) 
Stage 3 41 (28.9) 38 (29.5) 37 (30.6) 
Type of chemotherapy Neo-adjuvant 45 (31.7)       42 (32.6) 37 (30.6) 
Adjuvant 97 (68.3) 87 (67.5) 84 (69.4) 
Type of drugs Anthracyclines 121 (27.0) 117 (27.3) 105 (24.9) 
 Taxanes 35 (7.8) 24 (5.6) 26 (6.2) 
 Corticorsteroids 47 (10.5) 43 (10.0) 47 (11.2) 
 Alkylating agents 178 (39.7) 172 (40.2) 163 (38.7) 
 Others 23 (5.1) 11 (2.5) 14 (3.2) 
 Antinausea 44 (9.8) 61 (14.3) 66 (15.7) 
 
Table 3: Anthropometry characteristics of participants 
Variable Description 
Baseline (1st Chemo*) Midline (2nd Chemo*) Final (3rd Chemo*) 
N=142 N=129 N=120 
Weight Mean(SD) 66.6 (13.7) 65.9 (13.4) 66.1 (13.2) 
 
Range(Min-Max) 71 (38 - 109) 76 (39-107) 67 (40-107) 
BMI Mean (SD) 25.8 (4.9) 25.5 (4.9) 25.5 (5.0) 
BMI Categorized Underweight N (%) 3 (2.1) 3 (2.3) 4 (3.3) 
 Normal N (%) 63 (44.4) 62 (48.5) 52 (43.3) 
 Overweight & Obese N (%) 76 (53.5) 63 (49.2) 64 (53.3) 
*Chemo refers to chemotherapy cycles 
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Weight change was derived by determining the 
differences in weight between first and second cycle 
(midline weight change) and first and third (overall 
weight change). Between the first and second cycle, the 
highest proportion (29.5%) of the patients did not 
experience any weight change, 28.7% gained 1 kg while 
20.9% lost 1 kg. In addition, 14.7% of participants 
gained 2 kg as indicated in Figure 1. 
Between the first and the third cycle, majority (24.2%) 
of the patients gained 2 kg, 18.3% gained 1 kg, 4.2% 
gained 3 kg and 1.7% gained 4 kgs. Among those who 
lost weight, 19.2% lost 1 kg, 11.7% lost 2 kgs while 
0.8% lost 4 kgs as indicated in Figure 1. The mean (SD) 
midline weight change was a gain of 0.2 kg (1.1) while 
mean (SD) overall weight change was a gain was 0.4 kg 
(1.6) among the cancer patients. A paired sample t test 
showed no significant difference between weight 
change at midline and overall weight change at 95% 
confidence interval as shown in Table 4. 
Weight change was further classified into three groups; 
weight gain (positive weight change), no change and 
weight loss (negative weight change). At midline 
(between the first and second cycle), 27.1% lost weight 
while close to half of the patients (43.4%) gained 
weight. At end line (between the first and third cycle), 
31.7% lost weight, 48.3% reported positive weight 
change, while 20.0% reported no change. 
Factors associated with weight changes 
Chi square tests were used to determine factors 
associated with both weight gain and weight loss. The 
study results showed that participants who were 
married significantly gained weight compared to their 
unmarried counterparts (p<0.05). Body Mass Index at 
the start  of chemotherapy was significantly (p<0.05) 
associated with weight gain with more overweight 
patients gaining weight compared to those who were 
underweight and normal as shown in Table 5. With 
regards to weight loss, the study also showed that 
patients who experienced diarrhea significantly 
(p<0.05) lost weight compared to their counterparts 
(Table 5). 
 
Figure 1: Weight Changes observed among Breast Cancer Patients 
 
   Table 4: Weight changes among Breast Cancer Patients at Midline and Overall 
Weight change Midline weight change a Overall weight change b p-value 
Mean(SD) 0.2(1.1) 0.4(1.6) 0.109 
Median 0.0 0.0  
a Weight change between the 1st and 2nd cycle 
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Table 5: Overall weight changes and associated factors 
Weight gain and associated factors 
  
Description 
Gained 1 kg 
n (%) 
Gained 2-5 kg 
n (%) 
Chi square value P-value 
Marital Status Married 8 (20.5) 31 (79.5) 9.579 0.048 
 
Single 1 (11.1) 8 (88.9) 
  
 
Divorced 0 (0) 3 (100) 
  
 
Widowed 2 (100) 0 (0) 
  
 
Separated 1 (50) 1 (50) 
  BMI Baseline underweight 1 (100) 0 (0) 6.309 0.043 
 
Normal  6 (33.3) 12 (66.7) 
   Overweight 5 (13.9) 31 (86.1)    
Weight loss and associated factors 
  
Description 
Lost 1 kg 
n (%) 
Lost 2-5 kg 
n (%) 
Chi square value P-value 
Diarrhoea  Yes 7 (46.7) 8 (53.3) 5.625 0.018 
  No 2 (10.5) 17 (89.5)     
 
4.0 Discussion 
A significant change in weight during chemotherapy is 
reported to be associated with a poor prognosis in early 
breast cancer patients (Gadéa et al, 2012; Kroenke et al, 
2005; Thivat et al, 2010). Weight gain is a common 
phenomenon in breast cancer patients associated with 
poor survival with reported evidence among post-
menopausal women and receiving chemotherapy (Caan 
et al, 2012; Campbell et al, 2007; Han et al, 2006). 
Results from our study reported 14.6% increase in the 
number of participants who gained weight between the 
first and third cycle with an overall mean weight change 
of 0.4 kg and mean weight change of 0.2kg at midline. 
These results are in line with findings from a Korean 
study which recorded a mean weight change of 0.3 kg 
after 3 months of starting adjuvant chemotherapy 
among early stage breast cancer women (Han et al, 
2006). Correspondingly, a study on weight change and 
its correlates among breast cancer women showed a 
mean weight gain of 1.7kg eighteen months after 
diagnosis (Chen et al, 2011). Another study reported an 
average weight gain of between 1.7-4.4 kg among breast 
cancer patients during early post chemotherapy years 
(Caan et al, 2012). Our results were also comparable to 
the Women's Healthy Eating and Living Study (WHEL) 
which observed 2.7 kg of mean weight gain among 1116 
women with stage I-IIIA breast cancer, 60% of whom 
reported weight gain within 4 years of diagnosis (Rock 
et al, 1999). 
In breast cancer, weight gain is caused by premature 
menopause as an adverse effect of chemotherapy which 
results to slowed metabolic rate hence more body fat is 
gained than lean mass. A strong positive correlation 
between pre-chemotherapy weight and midpoint and 
overall weight changes was experienced by 
participants. These results are comparable with findings 
from most studies carried out to compare weight 
changes and pre diagnosis weight (Demark-Wahnefried 
et al, 2012; Goodwin et al, 1999; Irwin et al, 2005) 
More participants who were married experienced 
weight gain compared to counterparts and this was 
statistically significant (p<0.05). The results are similar 
with findings from studies that indicate that married 
cancer patients were less likely to have more advanced 
cancer compared to the time at diagnosis, are more 
likely to receive proper treatment and nutritional care 
and less likely to die compared to their unmarried 
counter parts (Schwartz, 2014) and experience higher 
survival rates. These results contrast with a Turkish 
study which did not find marital status a factor of 
weight gain in breast cancer patients (Basaran et al, 
2011). Similarly another Chinese study found out that 
education, income and marital status were not 
significantly associated with weight change(Chen et al, 
2011). As much as married cancer patients were 
reported to gain weight, there is need to carry out 
nutritional education and counselling on the dangers of 
excessive weight gain during cancer treatment, 
appropriate dietary practices and the importance of 
physical activity to achieve better treatment outcomes 
With Regards to BMI, our study indicated that more 
overweight and obese patients at the start of 
chemotherapy gained weight compared to their 
counterparts. Our results concur with a study carried 
out by Vagenas et al (2011) which revealed that weight 
gains  of over five kilograms were observed between six 
and sixty months post-surgery among obese patients. At 
six-month post-surgery, more than half of women 
(57%) who participated in the study were overweight 
or obese, and by six-years post-breast cancer 68% of 
women were overweight or obese. According to  NH 
Comprehensive Cancer Collaboration (2011),  
treatment regimen, tamoxifen use, fatigue, decreased 
physical activity, decreased lean body mass, decreased 
resting energy expenditure, increased consumption of 
foods to cope with nausea, or treatment-related 
increase in appetite are attributed to weight gain 
amongst breast cancer patients. There is therefore need 
to ensure weight management interventions are 
initiated among patients at the start of treatment. 
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On the other hand, diarrhea was significantly associated 
with weight loss among breast cancer patients. A meta-
analysis of risk of gastrointestinal complications in 
breast cancer patients treated with neratinib indicated 
an increased risk of diarrhea 89%(95%CI=77-95%) 
among breast cancer patients though significant 
increase in patients taking neratibin compared to those 
in the control group(Jiang et al, 2017). In a study on 
prevention of 5- Fluorouracil induced diarrhea, those 
who received synbiotics were less likely to suffer 
diarrhea(Osterlund et al, 2007).Diarrhea in cancer 
patients occurs as a side effect of treatment or the 
cancer itself(Cancer Research UK, 2017). A number of 
chemotherapy drugs   irritate the lining of the digestive 
system which occurs days after treatment. In addition 
to killing cancer cells, Chemotherapy also tends to kill 
fast growing cells like those of the intestine causing 
damage leads to diarrhea (Mayo Clinic, 2015). Diarrhea 
is a factor for significant unintentional weight loss 
defined as>5% loss of the usual body weight in the last 
6-12 months among cancer patients. However, minimal 
studies have been carried out to explain the correlation 
between diarrhea and weight loss specifically among 
breast cancer patients. In Kenya, there is therefore need 
for oncologists managing breast cancer patients to 
identify cases of diarrhea among these patients to 
ensure adequate measures are put in place to address it 
early and prevent it. 
Study Limitations 
Due to financial constraints, the study adopted a 
prospective cohort study design where patients were 
followed up for a period of 3 months instead of 6 
months during which their cycles are completed. 
Kenyatta National Hospital does not assess patient 
tumor grading and staging of the cancer after every 
cycle hence the study did not consider changes in the 
severity of cancer in relation to weight changes that 
occurred.  
5.0 Conclusion  
Majority of breast cancer patients were overweight and 
obese at diagnosis and most of them experienced 
weight gain compared to their counterparts. There is an 
increase in number of breast cancer patients who gain 
weight with continued chemotherapy. A higher number 
of patients who were married experienced weight gain 
than their unmarried counterparts. Diarrhea is 
associated with weight loss among breast cancer 
patients on chemotherapy. There was no association 
between age and weight gain as indicated in previous 
studies with larger sample sizes and longer follow ups 
periods 
Weight management interventions should be integrated 
in management of breast cancer patients.  
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